<DOC>
	<DOCNO>NCT01587495</DOCNO>
	<brief_summary>The investigator study learn dose safety ertapenem woman suspect serious infection less 42 day delivery infant .</brief_summary>
	<brief_title>Pharmacokinetics Safety Ertapenem Postpartum Period</brief_title>
	<detailed_description>Ertapenem receive FDA approval indication acute pelvic infection , though pharmacokinetic data guide dose ertapenem postpartum woman . The physiologic change postpartum period make likely special population require dose modification achieve desire therapeutic target . The objective study obtain detailed knowledge pharmacokinetics ertapenem postpartum period result improve guideline maternal dose neonatal exposure . This prospective , open-label , single center , pharmacokinetic study ertapenem woman diagnose postpartum endometritis . Subjects include 24 woman receive treatment diagnosis postpartum endometritis ertapenem Duke University Hospital Labor &amp; Delivery Unit . Each patient participate study approximately 7 day , though total study duration expect approximately 12 month . Descriptive statistic subject calculate . The appropriate non-compartmental pharmacokinetic parameter compute , include AUC24 , AUCss , Cmax , CL , Vss , t1/2 . All subject receive one dose study drug follow safety , plan internal review safety data follow completion 12 patient . Nursing infant study subject also follow safety due potential exposure study drug breastmilk .</detailed_description>
	<mesh_term>Endometritis</mesh_term>
	<mesh_term>Ertapenem</mesh_term>
	<criteria>18 year age old time enrollment . Postpartum period &lt; 42 day time enrollment . Sufficient venous access permit administration study medication . 2 clinical sign postpartum endometritis : Oral body temperature &gt; 101oF time , temperature 100.4 two occasion 6 hour apart . Maternal tachycardia parallel temperature . Uterine tenderness Purulent vaginal discharge Findings advance endometritis : dynamic ileus , pelvic peritonitis , pelvic abscess , bowel obstruction , necrosis low uterine segment . History previous hypersensitivity reaction beta lactams . Receiving valproic acid divalproex sodium . Creatinine clearance &lt; 30 mL/min calculate CockroftGault equation . Subject medical condition , opinion investigator , would interfere pharmacokinetic evaluation medication , place subject unacceptable risk injury , render subject unable meet requirement protocol . Previous participation study . Exposure ertapenem week prior study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>